Evaluating the long-term effects of a booster dose of MVA-BN vaccine for monkeypox
Official title: Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Run by Assistance Publique - Hôpitaux de Paris · NCT06885853 · Data updated 2026-11-12
This study is testing how well a booster dose of the MVA-BN vaccine works over time in men over 18 who have already had two doses to help protect against monkeypox.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, Paris) |
| Status | Recruiting |
| Started | May 7, 2025 |
| Main results expected | November 2026 |
| Study ends | November 2027 |
| Registry record updated | May 15, 2025 |
| Trial ID | NCT06885853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are men over 18 who have received two doses of the MVA-BN vaccine and are eligible for a booster.
✕Probably not a fit
Patients with a history of confirmed monkeypox or contraindications to vaccination will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the long-term immunogenicity of a booster dose of the MVA-BN vaccine, which is used to prevent monkeypox. The study focuses on men over 18 years who have previously received two doses of the vaccine and are eligible for a booster. Given the recent emergence of monkeypox outbreaks, particularly among high-risk populations, this research is critical for understanding the vaccine's effectiveness over time. Participants will also be eligible for HIV pre-exposure prophylaxis (PrEP) treatment, which adds an important layer to the study's public health implications.
Why it matters
Potential benefit: If successful, this study could enhance vaccination strategies and improve protection against monkeypox for at-risk populations.
How similar studies have gone: Other studies have shown promising results with similar vaccine approaches, particularly in enhancing immunogenicity through booster doses.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men aged over 18 years * Have received two doses of MVA-BN vaccine as an initial schedule * Eligible for a booster dose of MVA-BN (according to the HAS recommendation) * Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment * Covered by social security (excluding AME) Exclusion Criteria: * History of mpox (virologically confirmed) * Be under guardianship or curatorship * Be subject to a judicial protection measure * Have a contraindication to vaccination against mpox
Where it's running
-
CIC 1417Cochin-Pasteur
Paris, Paris, France Recruiting
Study contacts
- Principal investigator: Liem Binh Luong Nguyen, Degree medical doctor — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Liem Binh Luong Nguyen, Degree medical doctor
- Email: liem.luong@aphp.fr
- Phone: 0033 1 58 41 28 58
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safety, tolerability, and how the body processes BSY001 after single and multiple doses
This trial will test whether BSY001 is safe, well tolerated, and how it is absorbed and cleared when given once or multiple times to healthy adults aged 18–50.
-
Two-dose MVA monkeypox live vaccine in adults
This trial will test whether two doses of an MVA-strain monkeypox live vaccine are safe and produce an immune response in adults, including healthy people, men who have sex with men, and people living with HIV.
-
Follow-up of monkeypox cases and smallpox vaccine recipients
This project will follow adults who had monkeypox and people who received smallpox vaccine doses to see if immune responses remain strong over time and if any lasting physical or psychological effects develop.
-
Observational study of monkeypox infection in Brazil
This study is trying to see how different health factors affect the risk and severity of monkeypox in people in Brazil.
-
Understanding immune responses to monkeypox vaccination in high-risk individuals
This study is trying to see how well the monkeypox vaccine works in people at high risk, including those living with HIV, by looking at their immune responses after getting vaccinated.
-
mRNA vaccine (BNT166a) for mpox and smallpox prevention in adults in Africa
This tests whether two doses of the mRNA vaccine BNT166a are safe and produce an immune response in healthy adults in Africa, including people who have or have not had prior smallpox or mpox exposure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.